Technology
Health
Biotechnology

Ultragenyx Pharmaceutical

$64.65
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$4.39 (-6.36%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell RARE and other stocks, options, ETFs, and crypto commission-free!

About

Ultragenyx Pharmaceutical Inc. Common Stock, also called Ultragenyx Pharmaceutical, is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Read More Its product includes Mepsevii and Crysvita. The company was founded by Emil D. Kakkis on April 22, 2010 and is headquartered in Novato, CA.

Employees
610
Headquarters
Novato, California
Founded
2010
Market Cap
3.51B
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
543.14K
High Today
$68.88
Low Today
$64.56
Open Price
$68.42
Volume
298.96K
52 Week High
$90.98
52 Week Low
$37.44

Collections

Technology
Health
Biotechnology
Pharmaceutical
Biopharmaceutical
2014 IPO
US
North America

News

MarketBeatMar 10

Stock Price, News, & Analysis for Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologics product candidate includes Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII. The company is developing various biologics product candidates, including Burosumab, a human monoclonal antibody that ...

2
Simply Wall StMar 2

Is Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) A Financially Strong Company?

Small-cap and large-cap companies receive a lot of attention from investors, but mid-cap stocks like Ultragenyx Pharmaceutical Inc.

4
Seeking AlphaFeb 20

Ultragenyx Pharmaceutical Inc. 2018 Q4 - Results - Earnings Call Slides

The following slide deck was published by Ultragenyx Pharmaceutical Inc. in conjunction with their 2018 Q4 earnings call. 1 39 Click to enlarge Notes:...

30

Earnings

-$2.09
-$1.46
-$0.84
-$0.21
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 6, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.